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Metallothioneins (MTs) are low-molecular-weight (6–7 kD) nonenzymatic proteins (60-68 amino acid residues, 25-30% being 
cysteine) ubiquitously expressed in the animal kingdom. In the central nervous system (CNS), three MT isoforms are known, 
namely MT-I, MT-II, and MT-III. MT-I and MT-II (MT-I+II) are regulated and expressed coordinately and are currently the best 
characterized MT isoforms. This review will focus on the expression and roles of MT-I+II in the CNS. MT-I+II are implicated 
in diverse physiological and pathophysiological functions, such as metal ion metabolism, regulation of the CNS inflammatory 
response, protection against reactive oxygen species and oxidative stress, reduction of apoptotic cell death, and stimulation of 
neuroregeneration and brain tissue repair in vivo. Accordingly, brain tissue damage and neurodegeneration during pathological 
conditions and the accompanying mortality and clinical symptoms are altogether significantly increased in MT-I+II deficient 
mice, while the opposite is observed after medical MT-II treatment and in MT-I overexpressing mice. Consequently, MT-I+II are 
likely essential factors in CNS disorders, which suggests a potential therapeutic use of these proteins.
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INTRODUCTION 
In historical reports, a protein with a high affinity for heavy 
metals and an unusual cysteine abundance was discovered in 
horse kidney and subsequently, this protein was biochemically 
characterized and named metallothionein (MT)(1-3). Over the 
years, it has been shown that MT constitutes a superfamily 
of proteins, and a growing interest on MT has been evident 
(4-13). 
   MTs are low-molecular-weight (6–7 kD) nonenzymatic 
proteins (60-68 amino acid residues, 25-30% being cysteine) 
expressed ubiquitous in the animal kingdom and characteriz-
ed by a high content of zinc (Zn2+), copper (Cu+), and sulfur 
(present as cysteine)(4,7,10,14).
   In the CNS, there are three major MT isoforms, MT-I, MT-
II, MT-III (8-10,14-16), of which MT-III (also called growth 
inhibitory factor) only has been known since 1991 (17). 
   MT-I and MT-II (MT-I+II) are regulated and expressed co-
ordinately (18,19) and are the best characterized MT isoforms 
at present (6-9,12,20). Moreover, MT-I+II are the most exten-
sively distributed MT isoforms, being expressed in virtually 
all tissues (6,7,15,21). The regulation, expression, and putative 
roles of MT-III differ substantially from those of MT-I+II and 
are less well understood (7-9,12,15,17,21-27). This review will 
focus on the expression and functional significance of MT-I+II 
in the central nervous system (CNS). 
MT-I+II EXPRESSION IN THE CNS
Normal CNS
MT-I+II are expressed in the normal CNS, both during deve-
lopment and in adults (7,28-30). There is a general consensus 
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that astrocytes are the main cell type expressing MT-I+II, but 
in addition meningeal cells, ependymal cells, choroid plexus 
and endothelial cells show MT-I+II positivity. In contrast, 
microglia, oligodendrocytes, and neurons appear roughly de-
void of MT-I+II expression (7-9,28-35). Regarding MT-I+II 
expression in neurons, the data are conflicting as MT-I+II 
positive neurons have been described intermittently (36-39). 
However, it is generally agreed that the levels of MT-I+II in 
astrocytes are several-fold higher than in neurons (39).
CNS pathology
Pathological conditions in the CNS elicit a characteristic 
inflammatory response (40,41). Astrocytes are activated and 
show reactive astrogliosis (41-43), and macrophages are 
recruited from peripheral monocytes and resident microglia 
(44-48), as well as T lymphocytes and to a lesser degree B 
cells, and neutrophilic granulocytes are recruited in response 
to tissue damage in the CNS (41,44). During the CNS 
inflammatory response, both resident CNS cells and recruited 
leukocytes express various cytokines, major histocompatibility 
complex (MHC) and adhesion/costimulatory molecules, which 
ultimately lead to generation of reactive oxygen species 
(ROS) (49-56). ROS are highly toxic in the CNS – when 
their production is increased to a degree which overcomes 
the neutralizing effects of endogenous antioxidants, ROS 
are key mediators of oxidative stress, which is a hallmark 
of neurodegenerative diseases and cell death (49-51,57-60). 
Accordingly, the balance between pro- and anti-inflammatory 
factors determines the intensity and course of the inflammatory 
response including the levels of oxidative stress and neuro-
degeneration (48,61-64). 
   The expression of MT-I+II is significantly increased in CNS 
inflammation (7-9). In animal models, MT-I+II are increased 
following traumatic injury (65-70), administration of gliotoxic 
6-aminonicotinamide (6-AN)(71-74), excitotoxic kainic acid-
induced seizures (31,34,75,76), N-methyl-D-aspartate-induced 
excitotoxicity (77), and immobilization stress (78). Further-
more, MT-I+II are increased in a transgenic murine model of 
familial amyotrophic lateral sclerosis (ALS)(84,85), and in the 
myelin-deficient jimpy mouse (79) as well as in experimental 
autoimmune encephalomyelitis (EAE), the experimental 
model of the human demyelinating disease multiple sclerosis 
(80-83). MT-I+II expression is also upregulated in human 
neurological diseases - multiple sclerosis (own unpublished 
observations), Alzheimer´s disease, Pick’s disease (29,86-89), 
and ALS (89). 
   The cells increasing MT-I+II expression during pathological 
conditions are mainly reactive astrocytes, and to a lesser 
degree activated microglia/macrophages (22,31,34,66,67,70-
72,79,81,90-92). In addition, meningeal cells, ependymal cells, 
and endothelial cells become positive for MT-I+II during 
pathological conditions (7,32,88). The induction of MT-I+II in 
neuronal cells has not been consistently described (7-9,20).
Regulation of MT-I+II expression in CNS
MT-I+II expression is regulated in a coordinate manner 
(18). Various factors such as metals (Zn, Cu, Cd, Hg) 
(4,30,70,90), glucocorticoids (corticosterone, dexamethasone), 
catecholamines (norepinephrine, isoproterenol) (93-96), 
stress (78,96), and ionizing radiation (97-99) affect MT-I+II 
regulation and production (6,7,14,20). Another important factor 
influencing MT-I+II regulation in the CNS are inflammatory 
response-related stimuli such as proinflammatory cytokines 
(8,9,100). The cytokines interleukin-6 (IL-6), tumor necrosis 
factor-α (TNF-α), IL-3, and interferon-α increase MT-I+II 
expression in vivo in the CNS in a cytokine-specific manner 
as demonstrated by using transgenic mice overproducing 
these cytokines (91,92,101,102). Thus, by studying mice 
with genetic IL-6 deficiency [IL-6 knock-out (IL-6KO) mice], 
IL-6 has been demonstrated as a major inducer of MT-I+II in 
the CNS during pathological conditions (34,67,69,71,103). 
Finally, cellular oxidative injury due to formation of ROS is 
also an inducer of MT-I+II (6,7,104-110).
THE FUNCTIONAL SIGNIFICANCE OF MT-I+II IN THE CNS
The capability to specifically manipulate the MT-I+II genes 
in cells and mice, and pharmacological MT treatment studies 
have provided some answers regarding the roles for MT-
I+II in physiological and pathophysiological processes as 
well as the functional significance of MT-I+II during brain 
disorders. At present, MT-I+II are known to modulate several 
fundamental processes in the CNS: 1) metal ion metabolism, 
2) the neuroinflammatory response, 3) oxidative stress, and 
4) neurodegeneration versus neuroregeneration.
Metal ion metabolism
It is generally acknowledged that MT-I+II function in metal 
ion homeostasis in the brain, and particularly in Zn and Cu 
homeostasis as well as in the protection against heavy metals 
(1,15,21,30,70,111-114). By acting both as a donor and ac-
ceptor of essential metals Zn and Cu, MT-I+II may control 
Zn- and Cu-dependent proteins, enzymes and transcriptions 
factors, and regulate cellular Zn and Cu metabolism in res-
ponse to dietary and physiological changes (6,15,115-118). 
Hence, MT-I+II could serve as a metal ion reservoir from 
which apometalloproteins, including enzymes and zinc finger 
proteins (transcription factors, signaling and adapter molecu-
les), can acquire metal ions. In support of this, rapid exchange 
kinetics of Zn bound to MT-II, which is far greater than the 
exchange of Zn in other Zn proteins exists (119,120), and MT-
I+II can successfully donate Zn to a number of Zn dependent 
apometalloproteins in vitro (121). Reactivation in vitro of Zn 
requiring apoenzymes such as apocarbonic anhydrase and 
apocarboxypeptidase by MT-I+II retrieves their enzymatic 
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activity (120,122). Likewise, MT-II can donate Zn to trans-
cription factors and thereby to modulate DNA binding (123). 
The exchange reaction possibly occurs by a direct Zn donation 
from MT via protein-protein interaction (120).
   Given that MT-I+II regulate Zn and Cu, MT-I+II may have 
important roles in fetal development and in tissue responses 
to pathological conditions (70,115,124). Indeed, expression 
and regional distribution of MT-I+II during CNS development 
matched those of vesicular Zn (30). Also, Zn levels in plasma 
are related to the MT-I+II concentration (126,127), and tissue 
Zn accumulation shows an accurate relationship with MT-I+II 
expression (125-127), indicating that MT-I+II are involved in 
the regulation or processing of newly acquired Zn. In cases 
of dietary Zn or Cu deficiency, the MT-I+II levels in CNS are 
decreased significantly, resulting in considerable alterations 
in the neuroinflammatory response to brain injury (70). Ac-
cordingly, mice with genetical MT-I+II deficiency [MT-I+II 
knock out (MT-I+IIKO) mice)] are more sensitive to dietary Zn 
restriction as well as to Zn toxicity than normal mice (117). 
   MT-I+II are likely important in the protection against heavy 
metal ions as MT-I+II are involved in detoxification and sto-
rage of these metals (112,114,128). Thus, MT-I+II deficient 
astrocytes are more sensitive to methylmercury than astrocytes 
with intact MT-I+II expression, and MT-I gene transfection 
in MT-I+II deficient astrocytes resulted in increased resista-
nce to methylmercury (114,129). Using transgenic mice with 
overexpression of MT-I (MTTg* mice), it was demonstrated 
that MT-I protects against Cd lethality and toxicity (130), 
and MT-I+IIKO mice are far more susceptible to this metal 
(10,131,132) relatively to normal mice. Since both excess 
concentrations of Zn and heavy metals are highly toxic in 
the CNS (15,129,133-135), the roles of MT-I+II in metal ion 
regulation are likely neuroprotective (4,21,114).
Immunomodulation 
MT-I+II exert immunomodulatory roles in vitro and in vivo. 
Induction of MT-II mRNA and MT protein in vitro inhibited 
monocyte activation including cell adhesion, IL-1β levels, and 
the respiratory burst (136). The MT levels of monocyte-derived 
cell lines influence cell adherence, invasion and the oxidative 
burst (137,138), and MT-I+II significantly decrease the ability 
of macrophages to induce T lymphocyte proliferation in vitro 
(139). In addition, MT-I+II inhibit the antigen-specific humoral 
response of lymphocytes (140) and decrease the number of IgG 
secreting lymphocytes (141). MT-I+II reduce cytotoxic T cell 
activity by more than 70%, the proliferative response of T cells 
to cytokines, as well as the target cell killing and lymphocytic 
expression of CD8 (142). MT-I+II have been shown to in vivo 
modulate CNS immune responses in diverse pathological con-
ditions. Hence, the recruitment of macrophages, T lymphocytes 
and bone marrow progenitor cells in CNS pathological proces-
ses was significantly increased in MT-I+IIKO relatively to wild 
type mice (66,68,83,143), while both endogenous (transgenic) 
MT-I overexpression and exogenous MT-II treatment during 
CNS inflammation resulted in the completely opposite pattern 
with a significant reduction in macrophages and lymphocytes 
(8,9,65,74,81). This MT-I+II-dependent immunomodulatory 
effect is likely neuroprotective, since ongoing inflammation 
may lead to neurodegeneration and neurological disorders 
(49-51,54,56,91,92,147-150).
   The detailed mechanisms of actions of MT-I+II in redu-
cing both macrophage and T cell recruitment are not fully 
clarified, but MT-I+II may affect these cells by interference 
with membrane-associated molecules (53,54,56). Indeed, MT-
I+II can bind to the surface of macrophages (139), T and B 
lymphocytes (144) in vitro, and probably affect surface mole-
cules important for leukocyte activation and/or recruitment. 
In agreement with this, MT-I+II reduced the expression of 
MHC (142) and adhesion molecules such as ICAM and Mac1 
(143). On the other hand, the MT-I+II-induced modulation of 
CNS inflammatory response could likely be caused by altered 
cytokine levels. During CNS inflammation, MT-I+II reduced 
the expression of the proinflammatory cytokines IL-1β, IL-6 
and TNF-α as well as stimulated both reactive astrogliosis and 
the levels of antiinflammatory growth factors such as basic 
fibroblast growth factor (bFGF), transforming growth factor-β 
(TGF-β), neurotrophin-3 (NT-3) and -4 (NT-4) and vascular 
endothelial growth factor (VEGF), as it was demonstrated in 
genetically modified (MT-I+IIKO and MTTg*) mice and in 
animals treated with MT-II (8,9,31,65,66,68,73,74,81-83). The 
proinflammatory cytokines IL-1β, IL-6 and TNF-α orchestrate 
immunoresponses and have several activating functions during 
CNS inflammation (52,53,56). They are potentially deleteri-
ous or beneficial, depending on their concentration as well as 
the site and duration of action (54,61,63,64,145,146). Hence, 
excess or prolonged production of proinflammatory cytokines, 
such as in genetically manipulated mice can lead to chronic 
inflammation and functional CNS disorders (91,92,147-150). 
The MT-I+II-induced inhibition of IL-1β, IL-6 and TNF-α 
could likely regulate the response of inflammatory cells and 
serve important neuroprotective roles. In addition, the MT-
I+II-induced stimulation of the growth factors bFGF, TGF-
β1, NT-3 and VEGF in the pathological CNS (65,68,74) may 
exert supplementary anti-inflammatory and neuroprotective 
functions (52,56,151-160). 
   The above-mentioned effects of MT-I+II remind of the im-
munomodulatory actions of glucocorticoids, which selectively 
inhibit proinflammatory cytokines and stimulate anti-inflam-
matory cytokines and thereby push the immune reaction away 
from a TH1 and toward a TH2 pattern (161,162). Since cortico-
sterone and dexamethasone can induce MT-I+II expression in 
the brain (94-96), it might be that glucocorticoid hormones and 
MT-I+II have yet unknown additive and/or synergistic actions 
during pathological conditions. Another possibility is that some 
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of the immunomodulatory actions of glucocorticoids in the 
brain are mediated in part by MT-I+II, as intranasal admini-
stration of glucocorticoids in humans increased significantly 
MT-II mRNA in peripheral leukocytes (163). Also, patients 
with ulcerative colitis, who are steroid-refractory and respond 
poorly to glucocorticoid treatment, express low levels of MT-
II, while patients in remission, who respond to glucocorticoid 
treatment, show high MT-II levels in inflammatory cells (164). 
In agreement with this, MT-I+II induction in mice during in-
fluenza virus infection could be inhibited by administration 
of a glucocorticoid receptor antagonist (165), which reveals 
a direct role of glucocorticoids in MT-I+II induction during 
pathological conditions. Nonsteroidal anti-inflammatory drugs 
such as diclofenac, indomethacin and piroxicam also induce 
MT-I mRNA and MT proteins (166), as do antirheumatic drugs 
such as D-penicillamine (167). Therefore, it is likely that the 
mechanisms of action of both steroidal and nonsteroidal anti-
inflammatory drugs involve MT-I+II, suggesting a pivotal role 
for MT-I+II in regulating inflammation. Although the precise 
molecular mechanisms underlying these effects have yet to 
be clarified, it is likely that MT-I+II could be a very potent 
factor for the treatment of inflammatory and/or autoimmune 
conditions. Indeed, MT-II treatment during toxic neurodegen-
eration and traumatic brain injury could decrease both clinical 
and histopathological signs (65,74). MT-II treatment in EAE 
significantly improved clinical symptoms, induced disease 
remission and drastically decreased mortality (81). 
Oxidative stress 
A considerable oxidative stress occurs in CNS inflammatory 
responses due to the cytotoxic consequences of a misbalan-
ce between the formation of ROS and the ability of cells to 
produce antioxidants. Oxidative stress takes place when the 
production of ROS increases, scavenging of ROS by antio-
xidants decreases, or both. It is a major inducer of apoptotic 
cell death and a hallmark of neurodegenerative disorders (49-
51,57,59,60,146). Increasing data have emerged showing that 
MT-I+II are extraordinarily efficient free radical scavengers 
and antioxidant proteins with important roles during oxidative 
stress (4,12,14,15,68,83,105,107,108,110,168-181). In vitro 
studies have demonstrated that MT-I+II inhibit ROS-induced 
DNA degradation and tissue damage (106,177,178,182-188). 
In fact, MT-I+II could protect against ROS-induced DNA da-
mage with a much higher molar efficiency (almost 800-fold) 
than glutathione (GSH)(189). MT-I+II could also be important 
during oxidative stress by interacting with reduced GSH (184), 
MT-I+II can inhibit GSH depletion (183) and antagonize the 
deleterious effects of oxidative stress on catalase (183). MT-
I+II can functionally substitute for Cu/Zn-superoxide dismuta-
se (SOD) in the cellular defense against oxidative stress (190), 
and compensate for Cu/Zn-SOD deficiency in mice (191). In 
agreement with this, MT-I+II protect against neurotoxicity and 
oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine, which is used in experimental models of Parkin-
son’s disease (192), in which oxidative stress plays a key role 
(57,59). Cultured cells overexpressing MT-I are protected aga-
inst oxidative stress relatively to controls (177,178,187,188), 
and cells derived from MT-I+IIKO mice exhibit an increased 
sensitivity to oxidative stress (186,188,193). Hence, embryo-
nic or adult cells from MT-I+IIKO mice, despite their normal 
levels of GSH and normal activity of Cu/Zn-SOD, glutathione 
peroxidase or catalase, show enhanced ROS production and 
lipid peroxidation after exposure to tert-butyl hydroperoxide 
and paraquat (186,193). MT-I+II protect against the actions 
of electrophilic anticancer drugs and ionizing radiation, which 
are also agents causing oxidative stress and cell death (97-
99,173,186,194-196). MT-I+II play a key role in protection 
against oxidative stress induced in mitochondria following 
administration of mitochondrial-specific reactive oxygen 
generators (171), and MT-II overexpression in cells reduces 
drastically doxorubicin-induced mitochondrial ROS levels 
(197). During neuropathological conditions in MT-I+IIKO 
mice, the levels of antioxidants catalase, Mn-SOD and Cu/Zn-
SOD were increased along a significantly increased oxidative 
stress, as judged by increased levels of inducible nitric oxide 
synthase (iNOS), nitrotyrosine (NITT) and malondialdehyde 
(MDA)(31,66,68,83). In MT-I+II deficiency, even an increa-
sed expression of other antioxidants could not protect from 
increased oxidative stress levels, underlining the antioxidative 
and neuroprotective importance of MT-I+II in vivo. In IL-6KO 
mice with neuroinflammation, significant increases in oxidat-
ive stress levels have been detected relatively to normal mice 
(34,69,71), and in these mice all examined antioxidants other 
than MT-I+II were unaffected by the IL-6 deficiency, whereas 
the MT-I+II levels were clearly reduced (69,71). The levels 
of Cu/Zn-SOD, Mn-SOD and catalase were comparable in 
IL-6KO and normal mice, while MT-I+II were significantly 
decreased in the former (34,69), suggesting that MT-I+II are 
essential antioxidant factors in CNS inflammation. In addit-
ion, both endogenous (transgenic) MT-I overexpression and 
exogenous MT-II treatment during neuroinflammation protect 
significantly the CNS from ROS formation and oxidative stress 
in vivo (65,74,81,82). As numerous reports suggest that MT-
I+II are important antioxidants in vivo the methods to increase 
the MT-I+II levels during neurodegenerative disorders may 
become a new therapeutic approach.
Neurodegeneration and apoptosis
As oxidative stress is a major inducer of neurodegeneration 
and apoptosis (49,50,57,59,60,146), the antioxidant effects of 
MT-I+II may prevent apoptosis. On the other hand, MT-I+II 
per se can exert significant antiapoptotic functions, and the 
roles of MT-I+II in the control and inhibition of apoptosis 
have received increasing attention (8,9,12,16,31,65,66,70,74, 
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82,83,110,111,143,178,198-203). MT-I+IIKO mice exhibit a 
significantly higher numbers of apoptotic cells (mostly ne-
urons) during various CNS pathological conditions such as 
traumatic brain injury, excitotoxicity, EAE and during IL-6-
induced inflammation in vivo (31,66,83,143). MT-I overex-
pressing mice show significantly reduced apoptotic cell death 
in CNS inflammation (65,74), and in vivo MT-II treatment 
following traumatic brain injury, neuroglial degeneration or 
EAE significantly reduced CNS neurodegeneration and apop-
tosis (65,74,82). Interestingly, the apoptotic neurons observed 
in the injured brains were always MT-I+II-negative (65,74), 
suggesting that MT-I+II expression prevents apoptosis and/or 
neutralizes apoptotic signals. In agreement with this, suppres-
sion of the MT-I+II production in human T cells resulted in 
apoptosis, in a dose-dependent manner (201), and reduction of 
MT-I+II during ALS increased significantly the loss of motor 
neurons, also dose-dependently (85). These effects of MT-I+II 
are very interesting from a therapeutic point of view, in that 
CNS injury is often followed by a spread of tissue damage 
(secondary degeneration and apoptosis), resulting in neuronal 
loss substantially greater than predicted by the severity of the 
primary injury.
   The precise mechanisms through which MT-I+II can affect 
apoptosis are yet unknown, but several possibilities are like-
ly. At first, MT-I+II are extraordinarily efficient antioxidants, 
which in itself could explain the mechanism of action regarding 
apoptosis in the CNS (57,59,60). Secondly, MT-I+II are major 
factors controlling Zn and Cu (1,15,21,70,113,116,117,204), 
which in exceeding amounts can cause neuronal toxicity and 
death (133-135,205-208). Thirdly, the MT-I+II-induced inhi-
bition of macrophages and T lymphocytes in the CNS could 
reduce the number of cells suffering from apoptosis, in that 
an ongoing inflammatory response may initiate cytokine-
mediated cascades leading to increased levels of proteases, 
complement factors, eicosanoids, adhesion/costimulatory 
molecules, vasoactive amines and free radicals, which can 
affect the apoptosis pathway (49-51,54,56,61,209). To this 
may be added that apoptosis could also be due to the lack of 
proper astroglial functioning, as astrocytes are a main source 
for trophic factors in the brain and exert neuroprotective ac-
tions (4,42,68,72,210-213). In addition, MT-I+II presumably 
could affect directly critical steps in the signal transduction 
cascade leading to apoptosis, including proto-oncogenes and 
tumor suppressor protein p53 (57,59,214), as proto-oncoge-
nes protect against apoptosis, while p53 promotes apoptosis 
(59,60,214-216). Indeed, the levels of p53 were increased in 
MT-I+IIKO mice relatively to normal mice (200,203), and anti-
sense down-regulation of MT-I+II was followed by decreased 
levels of proto-oncogenes bcl-2 and c-myc and increased levels 
of p53 (198). This response of proto-oncogenes and p53 was 
reversed completely in MT-II overexpressing cells (198), and 
apo-MT overexpression in tumor cells promoted increased cell 
survival and growth by inducing a p53-null state (217). One 
of the mechanisms for this action could be the sequestration 
of Zn by MT-I+II in the cell nucleus, whereby Zn-depen-
dent gene expression and signaling pathways are suppressed 
as well as zinc finger-containing molecules are inactivated 
(5,6,104,218,219). In addition, MT-I+IIKO mice displayed 
increased immunoreactivity for caspase-1, activated caspase-3 
as well as cytoplasmic cytochrome-c (31,83), which are also 
involved in the critical steps leading to apoptosis (57,59). In 
agreement with this, caspase-1, caspase-3, and cytoplasmic 
cytochrome-c were significantly decreased in MTTg* mice 
and after MT-II treatment during neuroinflammation (74,82). 
MT-II overexpression in cells effectively inhibits doxoru-
bicin-induced apoptosis and mitochondrial cytochrome-c 
release and caspase-3 activation (197). Moreover, the levels 
of nuclear factor kappa B (NFκB), a key signal leading to ap-
optosis (59,60), were increased after a traumatic brain injury 
in MT-I+IIKO mice and in rats with decreased MT-I+II levels 
relatively to animals with normal MT-I+II expression (70). It 
was demonstrated that MT-I+II can interact with NFκB (221), 
and NFκB activity and concentration were significantly increa-
sed in vitro and in vivo in MT-I+II deficiency (31,220,222), 
and MT-I+IIKO mice showed increased NFκB levels during 
excitotoxicity relatively to controls (31). Taken together, these 
data support that MT-I+II have major antiapototic roles and 
may inhibit critical steps in the signal transduction cascade 
leading to apoptotic cell death. 
   Given the involvement of MT-I+II in cell proliferation, 
survival and apoptosis, it is not surprising that much attention 
has been drawn to the possible role of MT-I+II in cancer. 
Inhibition of MT-I synthesis in different tumor cell lines 
inhibits cell growth in a dose- and time-dependent manner 
(223). Inhibition of MT-II production in carcinoma cells 
reduced cell growth by 50-60% and induced apoptosis, while 
MT-II overexpression in these cells increased two-fold cellular 
proliferation relatively to control carcinoma cells (198). 
Moreover, MT-I+II positivty in bone marrow and peripheral 
blood samples of patients with acute leukemia was strongly 
associated with significant resistance to chemotherapy (202), 
which mediates its therapeutic effect by induction of oxidative 
stress and apoptosis (10,185,215). In the MT-I+II-negative 
cases of acute leukemia, the chemotherapy was more effective 
and the apoptotic action of chemotherapy was completed much 
faster than in the MT-I+II-positive cases (202). Interestingly, 
the study of MT-I+II expression during treatment of 
acute leukemia also demonstrates, that even though the 
chemotherapy eliminates leukemic cells, MT-I+II expressing 
cell populations survived and were able to increase during the 
treatment period, as they were capable of escaping apoptosis 
(202). In accordance to this, leukemic cells exhibited resistance 
to various anticancer drugs due to increased amounts of MT-
I+II protein and MT-II mRNA (224), and this resistance could 
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be reversed by specific inhibition of the MT-I+II synthesis 
(224). The apoptotic response to anticancer drugs is increased 
in cells with genetic MT-I+II deficiency relatively to wild-type 
cells (195,200). Thus, MT-I+II were demonstrated to have 
a major impact on chemotherapy resistance phenomena. In 
general, increased levels of MT-I+II in human tumors are 
associated with a high degree of malignancy and a poor 
response to anticancer drugs (14,173,185,225-228). These 
MT-I+II-induced effects could be mediated by more than 
one mechanism. MT-I+II have significant antioxidative and 
antiapoptotic roles, which can counteract the effects induced 
by anticancer treatment. In addition, MT-I+II can sequester 
electrophilic antineoplastic agents and thereby directly 
neutralize the anticancer drugs (10,185,225). By regulating 
the activities of Zn-requiring metalloenzymes, MT-I+II 
might alter the therapeutic effectiveness of anticancer drugs 
(5,225). MT-I+II can protect against chemotherapy-induced 
mutations in cells as antisense-mediated reduction of MT-II 
levels drastically elevates spontaneous mutation rates (229). 
Thus, cell clones with clearly reduced MT-II levels were 
spontaneous mutators, with a mutation rate 5-10 times higher 
than control cells (229). Transgenic overexpression of MT-I 
could considerably reduce the spontaneous mutation frequen-
cies, as well as the mutation rate in Zn- and Cd-treated cells 
was inversely related to MT-I mRNA and MT-I+II protein 
levels (230). 
   Thus, a reduction in the MT-I+II levels can very likely inhi-
bit cancer cell resistance to various anticancer treatments as 
well as the levels of MT-I+II in tumor cells might be used as 
a prognostic marker. Specific induction of MT-I+II in healthy 
tissue of cancer patients but not in cancer tissue could be a 
successful adjunct to anticancer strategy, which may alleviate 
the problems with tumor cell resistance to chemotherapy as 
well as the toxic side-effects in healthy cells, which are major 
obstacles to the curative treatment of cancer. Interestingly, 
treatment with bismuth compounds has the ability to induce 
MT proteins in normal, healthy tissue, but apparently not in 
cancer tissue (231-233). This is due to the fact that bismuth 
accumulates in healthy tissue but is hardly taken up by cancer 
cells, and MT proteins are thus induced only in healthy tissue, 
which thereby becomes resistant to chemotherapy and radia-
tion, while the simultaneous antitumor activities of anticancer 
treatments remain uncompromised (231-233). The manipu-
lation of MT-I+II in both healthy and cancer tissue may result 
in more successful treatment of cancer. Hence, gene-directed 
techniques leading to cell-specific and tissue-targeted MT-I+II 
regulation deserve to be investigated with highest priority in 
the future.
Neuroregeneration
A major problem following brain injury is that neurons 
are susceptible to degeneration and injured axons hardly 
regenerate. In this regard, it is interesting that MT-I+II 
significantly promote reactive astrogliosis. Accordingly, 
during neuropathological conditions, MT-I+IIKO mice dis-
play a significantly reduced number of reactive astrocytes 
(31,66,68,73,83), while reactive astrogliosis is clearly 
increased during transgenic MT-I overexpression or after 
exogenous MT-II treatment in CNS inflammation in vivo 
(65,74,81,82). This MT-I+II-induced stimulation of astrocytes 
is likely important, because astrocytes have major functions 
during the acute phase and later stages of CNS inflammation 
(41,42,56,146,210-212,234,235). Astrocytes produce various 
neuroprotective factors and contain the highest level of various 
antioxidants in the brain (4,34,68,70,72,210-212,236-237). 
Astrocytes from different brain regions have the potential 
to influence growth and maintenance of adult neurons (213) 
and protect neurons against injuries (210,234). In addition, 
astroglia modulate the extracellular matrix and contribute 
to the formation of glial scar tissue and CNS tissue repair 
following brain damage (4,42,66,68,69,237). 
   The growth factors bFGF, TGF-β1, NT-3 and VEGF are 
anti-inflammatory and neuroprotective factors involved in an-
giogenesis and tissue regeneration (52,56,151-160). In CNS 
pathology, MT-I+II induce the expression of bFGF, TGF-β1, 
NT-3 and VEGF (65,68,74), and thus MT-I+II may further 
stimulate tissue recovery and neuroregeneration. Accordingly, 
brain repair after a traumatic lesion to the cortex was drastically 
reduced in MT-I+IIKO mice, which showed a lesion cavity in 
the cortex even at 90 days after the injury. In contrast, normal 
mice, in which MT-I+II levels are increased, showed prono-
unced angiogenesis and preservation of the brain tissue by 10 
days after injury as well as a complete tissue recovery after 
20 days (66,68). Neuroregeneration was significantly increa-
sed in MTTg* mice and in mice receiving MT-II treatment 
following a similar brain lesion (65). MT-I+II stimulated the 
expression of growth-associated protein (GAP-43)(a marker 
for synaptogenesis) as well as axonal plasticity and repair 
during neuronal injury (M. Penkowa, unpublished observa-
tions). Mice overexpressing MT-I showed reduced cerebral 
edema and a significantly reduced volume of injured tissue 
(42% smaller than that of control mice) after focal cerebral 
ischemia and reperfusion (39). Three weeks after reperfusion, 
MTTg* mice exhibited reduced sensorimotor defects and a 
significantly better motor performance relatively to normal 
mice (39). In EAE model, rats receiving MT-II treatment had 
a significantly reduced mortality and clinical symptoms in a 
dose- and time-dependent manner, and MT-II administration 
resulted in EAE disease remission (81). Treating mice with 
MT-II during neuroglial degeneration totally eliminated the 
mortality relatively to mice receiving control treatment (74). 
On the contrary, MT-I+IIKO mice were more susceptible to 
kainic acid administration and showed more convulsions and 
longer convulsion periods when compared to those of control 
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mice (31). MT-I+IIKO mice with EAE showed more severe 
symptoms and increased disease incidence and mortality 
relatively to normal EAE-sensitized mice (83). Reduction of 
MT-I+II clearly promotes the onset of ALS clinical signs and 
mortality in a dose-dependent manner as shown in a transgenic 
murine model of familial ALS (85).  Taken together, the above 
studies strongly indicate that MT-I+II have cardinal roles in 
neuroprotection after brain damage (Table 1).
CONCLUSION
The expression of MT-I+II is essential following CNS 
pathological conditions, while normal mice are able to develop 
and function independently of their MT-I+II expression. 
Hence, MT-I+II may not have critical roles during normal 
conditions or there might be a back-up system to compensate 
for MT-I+II deficiency. In contrast, during neuropathological 
conditions, MT-I+II have a fundamental role. MT-I+II influence 
significantly the inflammatory cells recruited to the CNS, 
levels of oxidative stress, neurodegeneration and cell death. 
MT-I+II stimulate CNS angiogenesis and neuroregeneration 
following brain injury. These functions provide some rationale 
for the highly preserved and represented in nature MT-I+II 
proteins. Since MT-I+II effectively address more than one 
process contributing to CNS pathology, MT-I+II-based the-
rapies might become a new approach in the treatment of 
neurological disease. 
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